Literature DB >> 7523798

Mechanisms of p53 alteration in acute leukemias.

A Schottelius1, U Brennscheidt, W D Ludwig, R H Mertelsmann, F Herrmann, M Lübbert.   

Abstract

Disruption of normal p53 expression is the most frequent genetic change occurring in various human solid tumors; it is mostly due to sequence alterations of the p53 coding region by missense mutations or to loss of an entire, functional allele of this gene. In the present study, possible mechanisms resulting in a disruption of regulated expression of wild-type p53 were examined in acute leukemias of either lymphoid (ALL) or myeloid (AML) phenotype. p53 transcript accumulation, nucleotide sequence and gene structure were analyzed in primary leukemic cells from 50 patients. p53-specific transcripts were detected in 26/26 cases of ALL and 16/23 cases of AML using reverse transcriptase (RT)-PCR. Sequencing of transcripts did not reveal any point mutations or deletions. Heterozygosity at a polymorphic Bg/II site within intron 1 was found in 4/28 leukemic samples, and loss of one allele was noted in one of these. In addition, a novel, leukemia-associated structural abnormality located within the 5' flanking region of the p53 gene and associated with the loss of heterozygosity was observed in cells from this patient with ALL. The MDM2 gene which inactivates p53 by binding to it was neither amplified nor rearranged in 28 leukemias studied. Thus, disruption of regulated p53 expression resulting in lack of detectable p53 mRNA even by RT-PCR occurs in about 30% of cases of AML; however, p53 alterations typical for human solid tumors are an infrequent event in most types of human acute leukemias.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7523798

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  10 in total

Review 1.  Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic.

Authors:  Muneera Al-Hussaini; John F DiPersio
Journal:  Expert Rev Hematol       Date:  2014-08       Impact factor: 2.929

2.  MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy.

Authors:  Kensuke Kojima; Marina Konopleva; Ismael J Samudio; Masato Shikami; Maria Cabreira-Hansen; Teresa McQueen; Vivian Ruvolo; Twee Tsao; Zhihong Zeng; Lyubomir T Vassilev; Michael Andreeff
Journal:  Blood       Date:  2005-07-12       Impact factor: 22.113

3.  Enhanced P53 and BAX gene expression and apoptosis in A549 cells by cis-Pt(II) complex of 3-aminoflavone in comparison with cis-DDP.

Authors:  Beata Kosmider; Izabela Wojcik; Regina Osiecka; Jacek Bartkowiak; Elzbieta Zyner; Justyn Ochocki; Pawel Liberski
Journal:  Invest New Drugs       Date:  2005-08       Impact factor: 3.850

Review 4.  Apoptosis in leukemias: regulation and therapeutic targeting.

Authors:  Ismael Samudio; Marina Konopleva; Bing Carter; Michael Andreeff
Journal:  Cancer Treat Res       Date:  2010

5.  p53 is critical for the Aurora B kinase inhibitor-mediated apoptosis in acute myelogenous leukemia cells.

Authors:  Takayuki Ikezoe; Jing Yang; Chie Nishioka; Akihito Yokoyama
Journal:  Int J Hematol       Date:  2009-12-16       Impact factor: 2.490

6.  The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.

Authors:  Guiyun Song; Benigno C Valdez; Yang Li; Jose R Dominguez; Paul Corn; Richard E Champlin; Borje S Andersson
Journal:  Leuk Lymphoma       Date:  2014-02-04

7.  The impact of p53 loss on murine plasmacytoma development.

Authors:  Sabine Mai; Francis Wiener
Journal:  Chromosome Res       Date:  2002       Impact factor: 5.239

8.  p53 status of newly established acute myeloid leukaemia cell lines.

Authors:  A Zheng; K Castren; M Säily; E R Savolainen; P Koistinen; K Vähäkangas
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

9.  Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells.

Authors:  Line Wergeland; Gry Sjøholt; Ingvild Haaland; Randi Hovland; Øystein Bruserud; Bjørn Tore Gjertsen
Journal:  Mol Cancer       Date:  2007-05-11       Impact factor: 27.401

Review 10.  Rational Combinations of Targeted Agents in AML.

Authors:  Prithviraj Bose; Steven Grant
Journal:  J Clin Med       Date:  2015-04-10       Impact factor: 4.964

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.